We're using endoscopy, not everyone does that. Objective corroboration of patients experience. Pharma industry interested in novel therapies. We feel really good about where we are with Bril and IBD. 1/3 of patients find that existing treatments are not effective. Will present top line findings in July in Boston at conference, as well as meeting with 3rd parties who want to look at data.

Phase 2 OM trial which DOES have placebo "serves to anchor" UP results.

Foam, gel, or pill -- future studies will include placebo arm.

How would OM drug be valued? Half a million people get OM. Unmet need is one of largest out there. Bril is fast tracked. True game-changing treatment. Potential valuation: if results continue through Phase 3, market is very significant. Will request Breakthrough Therapy designation.

Enrollment is a challenge, entry requirements are quite stringent. Have opened additional trial sites and think it will be completed this year.